DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR DEYERMINATION OF ACYCLOVIR IN POLYMERIC NANOPARTICLES by Tavares, Guilherme Diniz et al.
  Universidade de São Paulo
 
2012
 
DERIVATIVE SPECTROPHOTOMETRIC
METHOD FOR DEYERMINATION OF
ACYCLOVIR IN POLYMERIC
NANOPARTICLES
 
 
QUIMICA NOVA, SAO PAULO, v. 35, n. 1, pp. 203-206, SEP-OCT, 2012
http://www.producao.usp.br/handle/BDPI/36345
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Farmácia - FCF/FBF Artigos e Materiais de Revistas Científicas - FCF/FBF
Quim. Nova, Vol. 35, No. 1, 203-206, 2012
N
ot
a 
T
éc
ni
ca
*e-mail: diniztavares@usp.br
DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF ACYCLOVIR IN POLYMERIC 
NANOPARTICLES
Guilherme Diniz Tavares*, Gisele Miki Ishikawa, Talita Ferreira Monteiro, Carolina Zanolini, Érika Rosa Maria Kedor-
Hackmann, Nádia Araci Bou-Chacra e Vladi Olga Consiglieri
Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580, 05508-900 São Paulo - SP, Brasil
Recebido em 28/2/11; aceito em 13/6/11; publicado na web em 8/8/11
A derivative spectrophotometric method was validated for quantification of acyclovir in poly (n-butylcyanoacrylate) (PBCA) 
nanoparticles. Specificity, linearity, precision, accuracy, recovery, detection (LOD) and quantification (LOQ) limits were established 
for method validation. First-derivative at 295.2 nm eliminated interferences from nanoparticle ingredients and presented linearity 
for acyclovir concentrations ranging from 1.25 to 40.0 µg/mL (r = 0.9999). Precision and accuracy data demonstrated good 
reproducibility. Recovery ranged from 99.3 to 101.2. LOD was 0.08 µg/mL and LOQ, 0.25 µg/mL. Thus, the proposed method proved 
to be easy, low cost, and accurate, and therefore, an useful alternative to quantify acyclovir in nanoparticles.
Keywords: acyclovir; polymeric nanoparticles; derivative spectrophotometry.
INTRODUCTION
In recent decades, there has been a considerable interest in the 
research of drug delivery using particulate systems as carriers for small 
and large molecules. Accordingly, nanoparticles have been used as a 
physical approach to modify and improve the pharmacokinetic and 
pharmacodynamic properties of a large number of drugs.1 Nanocarriers 
are currently being investigated for many therapeutic applications to 
overcome typical drug delivery challenges, such as increasing physi-
cochemical stability, enhancing cellular uptake of poorly permeable 
molecules, reducing cellular and tissue clearance of drugs, as well 
as sustaining drug delivery.2,3 So, the therapeutic efficacy and safety 
of drugs can be significantly improved by targeted delivery using 
nanoparticles.4
Nowadays, much attention has been paid to the poly(alkylcyano-
-acrylate) (PACA) nanoparticles due to their ease of preparation, 
low toxicity and biodegradability. Thus, these systems are already 
employed in clinical development for cancer therapy.5 After oral 
administration, PACA nanoparticles can protect the active molecules 
and control their release by an erosion mechanism.6 On the other 
hand, the surface modification of these nanocarriers using polymers 
with specific properties has been reported to be a promising way 
to improve the oral bioavailability of drugs.7 Thereby, studies have 
established that a partially quaternized derivative of chitosan, N,N,N-
-trimethylchitosan (TMC), can be used as an absorption enhancer for 
large and/or hydrophilic compounds across intestinal epithelium.8-10 
TMC acts mainly by opening the tight junctions between epithelial 
cells to allow the paracellular transport of these compounds.11
As a consequence, recent nanoparticle systems exhibit new 
analytical challenges because of the wide variety of compounds in 
their composition and also, the need to detect smaller amounts of 
drugs. A significant number of techniques, specially spectrophoto-
metry12-14 and high-performance liquid chromatography (HPLC),15-17 
are described for the quantification of drugs in PACA nanoparticles. 
Conventional spectrophotometric methods are very susceptible to the 
presence of interferences in complex mixtures such as nanoparticules, 
requiring prior treatment or extraction of the analyte, and not always 
providing adequate response. Despite the undoubted advantages of 
using HPLC technique, this one has some limitations such as the 
high cost of instrumentation and operation, relatively long time for 
analysis and the need of experience in handling the equipment and 
processing samples. In addition, the disadvantages related to the use 
of solvents such as discharge, operator health and environmental 
damage encourage the development of simpler and faster methods, 
with smaller amounts of solvents and without prior extraction steps. 
In this sense, derivative spectrophotometric method with detection 
in UV is low cost and is easily applied to analysis of raw materials 
and pharmaceuticals, as well as in kinetic studies of drug release, 
detection of analyte in the presence of decomposition compounds, 
and many other applications.18 
Derivative spectrophotometry (DS) is based on so called derivative 
spectra which are generated from conventional or zero-order scan. 
The derivatization of zero-order spectrum can lead to the separation 
of overlapped signals and elimination of background caused by pre-
sence of other compounds in a sample without previous separation 
or purification. Nowadays, this technique is considered a very useful 
additional tool which helps to solve various analytical problems. Several 
applications have been found in many areas of analysis, especially in 
pharmaceutical.19-21 
Some methods employing DS were reported to the quantification 
of acyclovir (9-[2-hydroxyethoxymethyl]-9H-guanine, ACV) (Figure 
1) in order to quantify this drug in pharmaceutical dosage forms, such 
as injections and creams22 or in the presence of guanine, its main 
impurity.23 Nevertheless, according to our knowledge, there are no 
reports concerning the quantification of ACV in PACA nanoparticles 
by this technique.
In this sense, the aim of this work was to purpose a rapid and 
effective first-order spectrophotometric method to quantify ACV in 
Figure 1. Chemical structure of ACV
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empirical formulation containing poly(n-butylcyanoacrylate) (PBCA) 
nanoparticles coated or uncoated with TMC. 
EXPERIMENTAL
Apparatus and conditions
A Shimadzu® UV-1601 double-beam spectrophotometer with 1.0 cm 
quartz cells and data processing capacity was used. The first-order deriva-
tive (zero-crossing method) spectra were obtained over the 220.0-320.0 
nm range, Δλ = 2.0 nm, scaling factor = 1.0 and amplitude = ± 0.1. The 
determinations were made at 295.2 nm (1D295.2). Methanol:Acetonitrile 
(MeOH:ACN) (8:2 v/v) was used as solvent mixture. 
Chemicals
Acyclovir reference standard (~99% purity) was kindly supplied 
by Aché Pharmaceuticals Laboratories (São Paulo, SP, Brazil). 
Acyclovir raw material of pharmaceutical grade was kindly donated 
by Medley Pharmaceutical Industry (Campinas, SP, Brazil). The 
monomer n-butylcyanoacrylate was purchased from B. Braun La-
boratories (Tuttlingen, Baden-Württemberg, Germany). Chitosan 
(low molecular weight, 92% deacetylated, viscosity 20000 cps) and 
Dextran 70.000 were obtained from Sigma Chemical Company (St 
Louis, MO, USA). Methyl iodide was purchased from Merck (Dar-
mstadt, Hessen, Germany). All other chemicals and solvents used 
were of analytical grade. N,N,N-trimethylchitosan was synthesized 
by reductive methylation of chitosan based on a previously described 
method24 and 1H-nuclear magnetic resonance spectra was obtained 
(Figure 1S, supplementary material). 
Nanoparticles preparation
Synthesis of PBCA nanoparticles
Poly(n-butylcyanoacrylate) nanoparticles (PBCA) were obtained 
by emulsion polymerization according to the method described by 
Couvreur and Vauthier25 with some modifications: n-butylcyanoa-
crylate monomer (1.0%) was added dropwise under magnetic stirring 
(800 rpm) into 10.0 mL of aqueous solution (pH 2.5), containing 
Dextran 70 (1.0%). After 4 h, about 100.0 µL of 0.1 M NaOH was 
added, until neutralization of colloidal suspension.
Preparation of PBCA-TMC nanoparticles
Coated nanoparticles were prepared by incubation of TMC 
aqueous solution (2.5 mL, 0.5% w/v) in 5.0 mL of nanoparticles 
suspension under magnetic stirring (50 rpm) for 1 h. 
Method validation
Reference standard stock solutions 
Standard ACV was accurately weighed (100.0 mg) and transferred 
to a 250.0 mL volumetric flask. HCl solution (0.1 M, 1.0 mL) was 
added to promote total dissolution and the volume was completed 
with MeOH:ACN (8:2 v/v). This solution was diluted with the same 
solvent, obtaining the ACV concentration of 20.0 µg/mL.
Placebo solutions
PBCA nanoparticles (placebo 1) and PBCA-TMC nanoparticles 
(placebo 2)
An aliquot of 10.0 mL of the PBCA nanoparticles suspension (or 
PBCA-TMC nanoparticles suspension) was transferred to a 250.0 
mL volumetric flask followed by addition of HCl solution (0.1 M, 
1.0 mL), and the volume was completed with MeOH:ACN (8:2 v/v). 
Then, 5.0 mL were transferred to a 100.0 mL volumetric flask and 
the volume was completed with the same solvent. Finally, 15.0 mL 
were centrifugated (10.000 rpm, 60 min, at room temperature) and 
the supernatant was used for measurements.
Sample solutions
PBCA nanoparticles with ACV (sample 1) and PBCA-TMC 
nanoparticles with ACV (sample 2)
Aliquots of 100.0 mg of ACV and 10.0 mL of PBCA nanopar-
ticles suspension (or PBCA-TMC nanoparticles with ACV) were 
transferred to a 250.0 mL volumetric flask followed by the addition 
of HCl solution (0.1 M, 1.0 mL) to promote total dissolution of ACV 
and the volume was completed with MeOH:ACN (8:2 v/v). Then, 5.0 
mL of this solution were transferred to a 100.0 mL volumetric flask 
and the volume was completed with the same solvent. The final ACV 
concentration was 20.0 µg/mL. Finally, 15.0 mL of this last solution 
was centrifugated (10.000 rpm, 60 min, at room temperature) and 
the supernatant was used for measurements.
Blank solution
Blank solution was prepared by transferring 1.0 mL of 01.M HCl 
solution to a 250.0 mL volumetric flask and completing volume with 
MeOH:ACN (8:2 v/v).
Specificity
The specificity of the method was evaluated by the analysis of 
standard solution, placebo solutions (1 and 2) as well as sample so-
lutions (1 and 2). Zero-order spectra were obtained over the 220-320 
nm range. From this, first-order derivative spectra were obtained. 
Linearity
Aliquots from the stock solutions of ACV were transferred to 
volumetric flasks and diluted with blank solution to obtain the final 
concentrations of 1.25, 2.5, 5.0, 8.0, 10.0, 16.0, 20.0 and 40.0 µg/mL. 
Each solution was prepared in triplicate. The first-order derivative 
spectra (zero-crossing method) were obtained over the 220.0-320.0 
nm range and determinations were made at 295.2 nm. The linearity 
was evaluated by linear regression analysis, which was calculated by 
the least square regression method.
Precision and accuracy
Aliquots of 10.0 mL from placebos 1 and 2 were added to kno-
wn amounts of standard solutions of ACV (25.0, 100.0 and 200.0 
µg/mL). Each sample was diluted with blank solution to analytical 
concentrations (2.5, 10.0 and 20.0 µg/mL), centrifugated (10.000 
rpm, 60 min, at room temperature) and supernatants were used for 
measurements. Precision and accuracy were calculated intra- and 
inter-day as RSD and E, respectively, as established by ICH in the 
Validation of Analytical Procedure–Methodology.26
Detection (LOD) and Quantification (LOQ) limits
Detection and quantification limits were estimated by the slope 
and mean standard deviation of standard ACV concentrations em-
ployed to construct the calibration curve.26
Recovery
Aliquots of samples 1 and 2 (20.0 µg/mL of ACV) were added to 
known amounts of standard solutions of ACV (80.0, 130.0 and 180.0 
µg/mL). Each sample was diluted with blank solution to analytical 
concentrations (10.0, 15.0 and 20.0 µg/mL). Solutions were recorded 
in the range of 220.0–320.0 nm and determinations were made at 
295.2 nm. Recovery was performed in nine replicates.26
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RESULTS AND DISCUSSION
The literature describes the use of different solvents in order 
to disrupt the PBCA nanoparticles for subsequent quantification of 
the associated drug, such as chloroform,12 ethanol,13 methanol16 and 
acetonitrile.27 These solvents, as well as their mixtures in different 
proportions, were evaluated through visual observation with regard 
to their ability of efficiently disrupt nanoparticles. The best solvent 
composition was found to be MeOH:ACN (8:2, v/v); however, a 
previous addition of HCl solution (0.1 M, 1.0 mL) (pH 1.2) was 
necessary to ensure complete solubilization of ACV. 
The zero-order spectra from ACV in PBCA or PBCA-TMC 
nanoparticles showed complete overlapping as can be observed in 
Figure 2. Therefore classical UV method cannot be applied. So, 
to assure no significance of these signals from placebos, nominal 
derivative values were evaluated. The first-derivative (1D) spectra 
from placebo 1 and 2, ACV, and nanoparticle systems (uncoated 
and coated with TMC) were presented by Figure 3. In this figure, 
it is possible to observe that all interferences were cancelled out at 
the wavelength of 295.2 nm. 
In addition, in order to improve the 1D method, different smooth-
ing and scaling factors were tested, where a smoothing factor of Δλ 
= 2.0 and a scaling factor = 1.0 showed a suitable signal-to-noise 
ratio and spectra showed good resolution. A linear correlation (r 
= 0.9999) was obtained between peak amplitude at 295.2 nm and 
the corresponding concentration for ACV in the range of 1.25 and 
40.0 µg/mL (Figure 2S, supplementary material). The linear regres-
sion equation was found to be: y = 0.0024x + 0.0004.
Intra- and inter-day precision, calculated as RSD, and accuracy 
values are reported in Tables 1 and 2. Relative small amount of RSD, 
not exceeding the limit of 5.0%, with mean values for intra- and inter-
run assays were 0.79 and 1.87% for the PBCA nanoparticles (placebo 
1). For the PBCA-TMC nanoparticles (placebo 2) these values were 
0.65 and 2.89%, respectively, and confirmed the precision, reproduc-
ibility and repeatability of the first derivative method at 295.2 nm. 
Accuracy mean values (intra- and inter-day) were 101.6 and 101.0% 
for the PBCA nanoparticles (placebo 1), whereas for the PBCA-TMC 
nanoparticles (placebo 2) were 100.3 and 100.7%. 
LOD and LOQ were estimated as 0.08 µg/mL and 0.25 µg/mL, 
respectively. Recovery experiment was conducted to corroborate 
the accuracy of the proposed zero-crossing first-derivative spectro-
photometric method. The mean recovery value (n = 9) for PBCA 
and PBCA-TMC samples with standard ACV was 100.3 and 100.2, 
respectively (Tables 3 and 4), indicating acceptable accuracy. 
CONCLUSIONS
Up to now, no derivative procedures have been described for assay 
of ACV present in PACA nanoparticles preparations. As a result, a new 
derivative spectrophotometric method was developed for determina-
tion of this drug in polymeric nanoparticles coated or uncoated with 
TMC. This described method has eliminated the interference from 
excipients, allowing the quantification of ACV in these formulations 
with good accuracy. The method showed to be simple, rapid, sensitive 
Figure 2. Zero-order absorbance spectra of (a) PBCA-TMC with ACV (20.0 
µg/mL), (b) PBCA with ACV (20.0 µg/mL), (c) ACV (20.0 µg/mL), (d) PBCA-
TMC, (e) PBCA. Abs = absorbance
Figure 3. First-order derivative spectra of (a) PBCA with ACV (20.0 µg/mL), 
(b) ACV (20.0 µg/mL), (c) PBCA-TMC with ACV (20.0 µg/mL), (d) PBCA, 
(e) PBCA-TMC
Table 2. Intra- and inter-day assays for determination of precision and accuracy of DS method (295.2 nm, zero-crossing) for placebo 2
Intra-day Inter-day
Analytical concentrations (µg/mL) Meansa ± s.d. (µg/mL) RSD (%) E(%) Meansb ± s.d. (µg/mL) RSD (%) E (%)
2.5 2.49± 0.024 0.96 99.68 2.46 ± 0.10 4.06 98.4
10.0 10.05± 0.08 0.79 100.50 10.31 ± 0.26 2.52 103.1
20.0 20.19 ± 0.039 0.19 100.95 20.16 ± 0.42 2.08 100.8
a
 n = 3; b n = 9; s.d. = standard deviation; precision = relative standard deviation (RSD); E = accuracy.
Table 1. Intra- and inter-day assays for determination of precision and accuracy of DS method (295.2 nm, zero-crossing) for placebo 1
Intra-day Inter-day
Analytical concentrations (µg/mL) Meansa ± s.d. (µg/mL) RSD (%) E (%) Meansb ± s.d. (µg/mL) RSD (%) E (%)
2.5  2.53 ± 0.045 1.78 101.4  2.44 ± 0.072 2.95  97.6
10.0 10.21 ± 0.046 0.45 102.1 10.26 ± 0.170 1.65 102.6
20.0 20.28 ± 0.027 0.13 101.4 20.56 ± 0.210 1.02 102.8
a
 n = 3; b n = 9; s.d. = standard deviation; precision = relative standard deviation (RSD); E = accuracy.
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Table 3. Results obtained from recovery tests of ACV from PBCA nanopar-
ticles by DS method (295.2 nm, zero-crossing)
Concentration (µg/mL)
Standard Sample Final 
concentration
Found 
(meana ± s.d.)
Recovery 
(%)
80.0 20.0 10.0 10.01 ± 0.014 100.1
130.0 20.0 15.0 14.97 ± 0.024 99.8
180.0 20.0 20.0 20.24 ± 0.041 101.2
an = 3; s.d. = standard deviation.
Table 4. Results obtained from recovery tests of ACV from PBCA-TMC 
nanoparticles by DS method (295.2 nm, zero-crossing)
Concentration (µg/mL)
Standard Sample Final 
concentration
Found 
(meana ± s.d.)
Recovery 
(%)
80.0 20.0 10.0 9.93 ± 0.019 99.3
130.0 20.0 15.0 15.12 ± 0.028 100.8
180.0 20.0 20.0 20.10 ± 0.060 100.5
an = 3; s.d. = standard deviation.
and precise and could be easily applied in the determination of ACV 
associated to these nanocarries. Hence, first-derivative presented to 
be an useful analytical method for precise and accurate determination 
of ACV in PBCA and PBCA-TMC nanoparticles.
SUPPLEMENTARY MATERIAL
Available at http://quimicanova.sbq.org.br, in pdf file, with free 
access.
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Figure 1S. 1H-NMR spectra of the TMC
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Figure 2S. First-order derivative overlapped spectra of ACV standard. Concentrations were 1.25, 2.5, 5.0, 8.0, 10.0, 16.0, 20.0 and 40.0 µg/mL
